Brokerages Set Bruker Corp. (BRKR) Target Price at $25.51
Bruker Corp. (NASDAQ:BRKR) has been assigned a consensus recommendation of “Hold” from the twenty analysts that are currently covering the company. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $25.51.
BRKR has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Bruker Corp. from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Monday, November 7th. Wells Fargo & Co. cut shares of Bruker Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Janney Montgomery Scott raised shares of Bruker Corp. from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Wednesday, August 3rd. Leerink Swann initiated coverage on shares of Bruker Corp. in a research note on Thursday, November 10th. They issued a “market perform” rating and a $21.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price objective on shares of Bruker Corp. in a research note on Thursday, November 3rd.
Large investors have recently bought and sold shares of the stock. Capital Fund Management S.A. purchased a new position in shares of Bruker Corp. during the second quarter worth about $10,471,000. State Street Corp increased its position in shares of Bruker Corp. by 27.2% in the first quarter. State Street Corp now owns 1,527,696 shares of the company’s stock worth $42,770,000 after buying an additional 326,527 shares during the last quarter. Quantitative Investment Management LLC increased its position in shares of Bruker Corp. by 157.7% in the second quarter. Quantitative Investment Management LLC now owns 63,900 shares of the company’s stock worth $1,453,000 after buying an additional 39,100 shares during the last quarter. Smith Asset Management Group LP purchased a new position in shares of Bruker Corp. during the second quarter worth about $8,928,000. Finally, BlackRock Inc. increased its position in shares of Bruker Corp. by 118.8% in the first quarter. BlackRock Inc. now owns 13,454 shares of the company’s stock worth $377,000 after buying an additional 7,305 shares during the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.
Bruker Corp. (NASDAQ:BRKR) opened at 23.16 on Tuesday. The company has a 50-day moving average of $21.73 and a 200-day moving average of $23.45. Bruker Corp. has a 1-year low of $19.58 and a 1-year high of $29.85. The company has a market capitalization of $3.71 billion, a P/E ratio of 26.17 and a beta of 1.04.
Bruker Corp. (NASDAQ:BRKR) last posted its earnings results on Wednesday, November 2nd. The company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.12. The company earned $393.90 million during the quarter, compared to analysts’ expectations of $394.14 million. Bruker Corp. had a net margin of 9.02% and a return on equity of 26.05%. Bruker Corp.’s quarterly revenue was down .6% on a year-over-year basis. During the same period last year, the company posted $0.19 earnings per share. Equities analysts expect that Bruker Corp. will post $1.10 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 23rd. Stockholders of record on Monday, December 5th will be issued a $0.04 dividend. The ex-dividend date is Thursday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.69%. Bruker Corp.’s dividend payout ratio is currently 18.18%.
Bruker Corp. Company Profile
Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Stock Ratings for Bruker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corp. and related stocks with our FREE daily email newsletter.